Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06261489
PHASE2

Cannabis (THC vs. CBD) in Multiple Sclerosis

Sponsor: University of Calgary

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS). Participants will complete questionnaires and cognitive tests. They will be randomly assigned to receive either CBD or THC oil and will take the study drug for 15 weeks.

Official title: The Differential Effects of THC vs. CBD on Cognition in Persons With MS

Key Details

Gender

All

Age Range

18 Years - 59 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-12-05

Completion Date

2026-09

Last Updated

2026-01-14

Healthy Volunteers

No

Interventions

DRUG

THC

Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.

DRUG

CBD

Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.

Locations (1)

University of Calgary

Calgary, Alberta, Canada